4-AcO-DET

Discovery

4-AcO-DET was synthesized in 1958 by Albert Hofmann at Sandoz Laboratories in Basel, Switzerland,^[2] as part of a systematic program exploring 4-substituted tryptamine esters following the isolation of psilocybin and psilocin. The parent scaffold, N,N-diethyltryptamine (DET), had been first synthesized by Stephen Szára and reported in 1957. Hofmann and Franz Troxler also synthesized the pharmacologically active metabolite 4-HO-DET (ethocin) under the laboratory code CZ-74, alongside a phosphorylated structural analog CEY-19^[6] — both conceived as short-acting alternatives to psilocybin for clinical settings.

Clinical use

CZ-74 entered human use during the 1960s within the framework of psycholytic therapy, the European model of psychedelic-assisted psychotherapy.^[3] Hanscarl Leuner of the University of Göttingen deployed CZ-74 and CEY-19 across approximately 30 treatment centers in Europe; clinical reports described CZ-74 as producing "virtually no side-effects" at therapeutic doses.^[7] Alexander and Ann Shulgin later documented both 4-HO-DET and its acetate ester in TiHKAL (1997), noting that the ester appeared to show faster onset and increased potency beyond what simple prodrug conversion would predict.^[8]

Modern era

4-AcO-DET first appeared on the research chemical market in May 2001, sold as "ethacetin" or "ethylacybin".^[4] No formal clinical trials have been registered for the compound. Its parent scaffold DET is Schedule I under both the UN 1971 Convention on Psychotropic Substances and the U.S. DEA,^[9] but 4-AcO-DET itself remains unscheduled in most countries — a legal grey zone that has drawn increasing regulatory attention, including a withdrawn 2022 DEA proposal targeting related tryptamines.^[10]

Structural class

4-AcO-DET belongs to the 4-substituted tryptamine family, a class of indolealkylamine psychedelics that includes psilocybin, psilocin, and 4-AcO-DMT. The core structure is N,N-diethyltryptamine (DET) with a 4-acetoxy group (–OC(O)CH₃) attached at the indole 4-position. This acetoxy moiety makes 4-AcO-DET a structural ester prodrug: enzymatic hydrolysis cleaves the acetate group to yield 4-HO-DET (ethocin/CZ-74), the active 4-hydroxytryptamine.^[1]

The N,N-diethyl substitution on the terminal amine distinguishes 4-AcO-DET from 4-AcO-DMT (N,N-dimethyl) and 4-AcO-MiPT (N-methyl-N-isopropyl). This places it in the middle range of N,N-dialkyl bulk among 4-substituted tryptamines — smaller than the diisopropyl group, which retains substantial serotonin receptor affinity,^[11] but larger than the dimethyl group found in the psilocin series.

Molecular properties

The indole ring bears the acetoxy group at C-4 and a 2-(diethylamino)ethyl chain at C-3. At 274.36 g/mol, the compound exceeds its active metabolite 4-HO-DET (232.32 g/mol) by the mass of the acetyl moiety — meaning an equivalent weight of 4-AcO-DET delivers roughly 85% of the molar amount of active 4-HO-DET.^[12]

Stereochemistry

4-AcO-DET contains no chirality centers. The compound exists as a single achiral species and requires no stereo-specific designation.

Stability

In freebase form, 4-AcO-DET presents as a tan powder that is chemically unstable, degrading upon exposure to air, light, and moisture.^[4] Over months, material progresses from tan powder to a black tarry substance. Analysis of degraded samples identified 4-HO-DET as the primary breakdown product, along with two unidentified compounds of unknown pharmacological activity.^[4]

The degradation mechanism appears to involve polymerization rather than simple oxidation. Degraded samples may retain significant potency, but the presence of uncharacterized breakdown products introduces unknown risk. Conversion to a salt form and storage in airtight, frozen, dark conditions with desiccant may improve stability.^[4]

Mechanism of action

4-AcO-DET is a presumed prodrug that undergoes hydrolysis by serum esterases to yield 4-HO-DET (ethocin/CZ-74), the pharmacologically active compound.^[4][1] This parallels the psilocybin → psilocin conversion. Analysis of degraded 4-AcO-DET samples confirmed 4-HO-DET as the primary product, supporting the prodrug hypothesis.^[4]

The active metabolite 4-HO-DET acts primarily as a 5-HT₂A receptor agonist — the principal mechanism shared by tryptamine psychedelics. No binding data specific to 4-AcO-DET or 4-HO-DET have been published.safety citation needed Class-level data for 4-substituted tryptamines indicate strong 5-HT₂A affinity with high selectivity over other serotonin receptor subtypes.^[11][13]

Raithatha et al. (2024) found that 4-acetoxy tryptamines show somewhat weaker binding than their 4-hydroxy counterparts but retain similar target profiles across serotonin receptors.^[1] Shulgin noted that 4-AcO-DET may possess independent activity beyond prodrug conversion, based on faster onset and greater potency than expected from hydrolysis alone.^[8]

Pharmacokinetics

No human pharmacokinetic data have been published for 4-AcO-DET.safety citation needed The compound is believed to undergo rapid hydrolysis to 4-HO-DET via serum esterases, though the rate in humans is unknown. Raithatha et al. (2024) found that 4-acetoxy prodrugs demonstrated reduced pharmacological exposure compared with psilocybin, suggesting slower or less complete activation than phosphate ester prodrugs.^[1]

By analogy to Psilocin, the active metabolite 4-HO-DET is expected to be broken down by liver enzymes with secondary contribution from MAO-A (MAO-A).^[14] Studies of psilocin in humans report an half-life of 1.5–4 hours, time to peak blood levels of 1.8–4 hours after oral dosing, and bioavailability of approximately 53%.^[14] Whether the larger N,N-diethyl group of 4-HO-DET meaningfully alters these parameters is unknown.

Where it acts

As a serotonin 2A receptor agonist (via its metabolite 4-HO-DET), 4-AcO-DET is expected to act on the same brain circuits documented for other serotonergic psychedelics. No neuroimaging data exist for this compound. In studies of psilocybin and LSD, 5-HT₂A activation on cortical neurons disrupts the default mode network — the brain's self-referential processing system — while increasing communication between normally segregated brain regions.

This results in greater neural signal complexity and weakened sensory filtering, which maps onto the subjective experience: visual distortions arise from disrupted sensory gating, altered self-perception from default mode dissolution, and novel thought patterns from increased cross-network connectivity.

Why it matters

The leading theoretical framework, REBUS (Relaxed Beliefs Under Psychedelics), proposes that these compounds reduce the brain's confidence in its existing models of reality, allowing raw sensory and emotional input greater influence on conscious experience.citation needed Separately, serotonergic psychedelics may promote structural brain changes — new neural connections and strengthened synapses — through signaling cascades involving neurotrophin receptors.^[15] Whether 4-AcO-DET engages these neuroplasticity pathways with meaningful potency is unknown.

Toxicity

No lethal dose data have been published for 4-AcO-DET in any species. No animal toxicity studies specific to this compound were identified in tryptamine toxicology reviews.^[16][17] No case reports of adverse events, overdose, or death attributable to 4-AcO-DET exist in the published literature.

This absence may reflect limited detection rather than genuine safety: tryptamines are not included in standard toxicology screening panels, and their contribution to drug-related emergencies may be significantly underestimated.^[17]

Psychological risks

The psychedelic class risk profile applies to 4-AcO-DET by pharmacological inference. Acute psychological risks include anxiety, panic reactions, paranoia, and dysphoria. At high doses, thought loops, ego dissolution, and depersonalization may become severely distressing.

Prolonged psychotic episodes are documented for the serotonergic psychedelic class in individuals with personal or family history of psychotic disorders or bipolar disorder. Hallucinogen persisting perception disorder (HPPD) — persistent visual disturbances after psychedelic use — has been reported with tryptamine psychedelics, though reliable prevalence estimates do not exist. No published psychological adverse event data specific to 4-AcO-DET exist.safety citation needed

Tolerance and dependence

4-AcO-DET is not considered habit-forming. Tolerance develops rapidly after even a single dose, driven by 5-HT₂A downregulation in the frontal cortex.^[5] This tolerance is pharmacologically self-limiting: the same mechanism that reduces sensitivity also removes the reinforcement that would drive repeated use.

Tolerance half-life is estimated at approximately 3 days, with full reset at approximately 7 days. Cross-tolerance extends to other serotonergic psychedelics including psilocybin, LSD, and DMT. Related substituted tryptamines show low reinforcing effects and low abuse liability in animal studies.^[18]

Drug interactions

The primary pharmacological hazard is additive serotonergic activity when 4-AcO-DET is combined with other drugs acting on the serotonin system. The active metabolite 4-HO-DET is a 5-HT₂A agonist that may also interact with the SERT,^[19] creating multiple pathways for serotonin syndrome in combination.

Tramadol poses the most clearly documented danger. Tramadol blocks serotonin reuptake^[20][21] and is among the opioids most associated with serotonin syndrome.^[20] Case reports confirm severe and prolonged serotonin toxicity from tramadol combinations.^[22][21]

MAOIs would dramatically potentiate effects by blocking MAO-A, a key enzyme in metabolizing the active compound 4-HO-DET.^[14] This could produce unpredictable, prolonged, or dangerous serotonergic effects.

SSRIs and SNRIs may attenuate or unpredictably potentiate psychedelic effects. Risk of serotonin syndrome exists, particularly at higher SSRI/SNRI doses.

Lithium combined with serotonergic psychedelics has been associated with seizures and heart rhythm disturbances in case reports involving related tryptamines and lysergamides.safety citation needed

Cannabis may intensify subjective psychedelic effects and increase risk of anxiety and panic through mechanisms independent of the serotonin system.

Contraindications

No substance-specific contraindication data exist for 4-AcO-DET. The following are inferred from the 5-HT₂A agonist mechanism and class-level evidence.safety citation needed

Absolute contraindications:

• Personal or family history of psychotic disorders or schizophrenia — 5-HT₂A agonism may trigger or worsen psychotic episodes, the most consistently documented psychiatric risk across serotonergic psychedelics.
• Concurrent MAOI therapy — risk of dangerous and unpredictable serotonergic potentiation.
• Concurrent lithium therapy — seizure and heart rhythm disturbance risk documented for the psychedelic class.

Relative contraindications:

• Bipolar disorder — risk of triggering manic episodes.
• Concurrent SSRI/SNRI therapy — altered and unpredictable effects; serotonin syndrome risk at higher doses.
• Heart conditions — increased heart rate and blood pressure are reported for the serotonergic psychedelic class.
• Pregnancy and nursing — no safety data exist; serotonergic psychedelics are contraindicated due to unknown effects on fetal development.

4-AcO-DET occupies an ambiguous legal position in most jurisdictions. Its parent scaffold DET is internationally controlled under Schedule I of the United Nations 1971 Convention on Psychotropic Substances,^[9] but 4-AcO-DET itself is not separately listed in any international convention. Several jurisdictions control it under generic tryptamine provisions or structural analog statutes, while others have not addressed it specifically.

Analog and prodrug considerations

The Federal Analog Act potentially captures 4-AcO-DET as a "substantially similar" compound to DET (Schedule I) when intended for human consumption. The compound's dual status as both a structural analog of a scheduled substance and a prodrug for 4-HO-DET — an unscheduled but pharmacologically active tryptamine — creates layered legal complexity. The DEA's 2022 proposed rule, though withdrawn, signals continued regulatory attention to novel tryptamines in this structural class.